Vaxart (VXRT) Appoints Jeroen Grasman as CFO

Vaxart, Inc. (Nasdaq: VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025.

“We are delighted to welcome Jeroen to the Vaxart team,” said Steven Lo, Chief Executive Officer of Vaxart. “His extensive financial expertise and proven track record in the biotech sector, including his operational acumen and clinical development support, will be invaluable as we continue to advance our oral pill vaccine programs. We look forward to his contributions.”

Mr. Lo added, "We thank Phil for his dedication and service to Vaxart. He has played an important role in our progress, and we appreciate his commitment to ensuring a seamless transition.”

Mr. Grasman brings more than 20 years of financial leadership experience in the biotechnology industry. He most recently served as Chief Financial Officer at AltruBio, a clinical-stage private biotech company, from August 2021 to May 2025. During his tenure at AltruBio, Mr. Grasman led finance and operations and helped scale the company for global clinical studies. Before that, Mr. Grasman served as Vice President, Finance and Operations at PACT Pharma, a clinical-stage private biotech company. Prior to joining PACT Pharma, Mr. Grasman served as Vice President, Finance at Intarcia Therapeutics and before that spent more than 10 years at Genentech. Mr. Grasman earned a MSc in Applied Mathematics from Groningen University in the Netherlands and an MBA from Harvard Business School.

“I am excited to join Vaxart as the Company pioneers vaccination in an oral pill formulation,” said Mr. Grasman. “Vaxart’s innovative technology platform holds significant promise, and I look forward to working with the team to drive its continued development towards an accessible, effective, and convenient immunization solution for people around the world.”

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• Pershing Square Selling About 80.6m Shares In Universal Music - Bloomberg
• FG Merger II sets stockholder vote on BOXABL merger for June 9